The Right to Try Act offers a federal pathway for patients with life-threatening illnesses to access investigational drugs outside clinical trials, but using it to obtain psychedelic therapies like psilocybin or MDMA remains legally complex and practically difficult. While the 2018 law allows patients who have exhausted approved treatments to request experimental medicines directly from manufacturers, it does not compel any company to say yes, and most psychedelic developers have been reluctant to supply therapies outside controlled research settings.
On April 18, 2026, President Trump signed an executive order directing the FDA and…